Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer

Overview

Journal Oncol Hematol Rev

Date 2021 Apr 12

PMID 33841882

Citations 4

Authors

Kristy A Brown

Eleni Andreopoulou

Panagiota Andreopoulou

Affiliations

Soon will be listed here.

Abstract

Nearly 270,000 new breast cancer cases are predicted to be diagnosed in the USA in 2019 with more than 70% being estrogen receptor positive and treated using endocrine therapy. The suppression of estrogen biosynthesis or action via the use of ovarian suppression, aromatase inhibitors and selective estrogen receptor modulators/degraders, respectively, is effective in approximately 70% of women. The systemic inhibition of estrogen during breast cancer treatment is also associated with side effects due to the important endocrine functions of this steroid hormone, including its role in the maintenance of energy homeostasis and bone health. The current work will present perspectives of the impact of endocrine therapy from the point of view of breast medical oncology, endocrinology, and basic science.

Citing Articles

A promising target for breast cancer: B7-H3.

Jiang Y, Liu J, Chen L, Qian Z, Zhang Y BMC Cancer. 2024; 24(1):182.

PMID: 38326735 PMC: 10848367. DOI: 10.1186/s12885-024-11933-3.

Editorial: Drug resistance in breast cancer - mechanisms and approaches to overcome chemoresistance.

Raman D, Cimpean A, De Miglio M Front Oncol. 2023; 12:1080684.

PMID: 36686836 PMC: 9847496. DOI: 10.3389/fonc.2022.1080684.

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.

Wang N, Yang Y, Jin D, Zhang Z, Shen K, Yang J Front Pharmacol. 2022; 13:967633.

PMID: 36091750 PMC: 9455597. DOI: 10.3389/fphar.2022.967633.

Metabolic pathways in obesity-related breast cancer.

Brown K Nat Rev Endocrinol. 2021; 17(6):350-363.

PMID: 33927368 PMC: 10410950. DOI: 10.1038/s41574-021-00487-0.

References

Sun L, Chen H, Liang J, Li T, Kao C . Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer. Br J Cancer. 2014; 111(9):1836-42. PMC: 4453737. DOI: 10.1038/bjc.2014.488. View

Chen Z, Maricic M, Aragaki A, Mouton C, Arendell L, Lopez A . Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int. 2008; 20(4):527-36. PMC: 2895418. DOI: 10.1007/s00198-008-0721-0. View

Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa M . Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006; 42(8):1077-82. DOI: 10.1016/j.ejca.2006.01.027. View

Zhang P, Li H, Tan X, Chen L, Wang S . Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013; 37(3):207-18. DOI: 10.1016/j.canep.2012.12.009. View

Burstein H, Lacchetti C, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016; 34(14):1689-701. DOI: 10.1200/JCO.2015.65.9573. View

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

Dhesy-Thind S, Fletcher G, Blanchette P, Clemons M, Dillmon M, Frank E . Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017; 35(18):2062-2081. DOI: 10.1200/JCO.2016.70.7257. View

Overbeek J, van Herk-Sukel M, Vissers P, van der Heijden A, Bronsveld H, Herings R . Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries. Diabetes Care. 2019; 42(3):434-442. DOI: 10.2337/dc18-2146. View

Van Poznak C, Hannon R, Mackey J, Campone M, Apffelstaedt J, Clack G . Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010; 28(6):967-75. DOI: 10.1200/JCO.2009.24.5902. View

10.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

11.

Santen R, Brodie H, Simpson E, Siiteri P, Brodie A . History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009; 30(4):343-75. DOI: 10.1210/er.2008-0016. View

12.

Petkov V, Miller D, Howlader N, Gliner N, Howe W, Schussler N . Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2017; 2:16017. PMC: 5515329. DOI: 10.1038/npjbcancer.2016.17. View

13.

Noto H, Goto A, Tsujimoto T, Noda M . Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7(3):e33411. PMC: 3308971. DOI: 10.1371/journal.pone.0033411. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

16.

Zahid H, Subbaramaiah K, Iyengar N, Zhou X, Chen I, Bhardwaj P . Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link. Int J Obes (Lond). 2017; 42(4):711-720. PMC: 5936686. DOI: 10.1038/ijo.2017.273. View

17.

Wilcken N, Hornbuckle J, Ghersi D . Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003; (2):CD002747. PMC: 8094405. DOI: 10.1002/14651858.CD002747. View

18.

Amir E, Seruga B, Niraula S, Carlsson L, Ocana A . Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011; 103(17):1299-309. DOI: 10.1093/jnci/djr242. View

19.

Chen L, Chubak J, Boudreau D, Barlow W, Weiss N, Li C . Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Res. 2017; 77(21):6033-6041. PMC: 5668156. DOI: 10.1158/0008-5472.CAN-17-0687. View

20.

Fleming S, Rastogi A, Dmitrienko A, Johnson K . A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999; 37(6):601-14. DOI: 10.1097/00005650-199906000-00009. View